Clinical Trials

EndocrineGastrointestinalThoracic

29 enrolled 25 charts

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03811002 2026-06-01

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3 Active not recruiting

544 enrolled 29 charts

Phase NA Active not recruiting

Lung Neoplasms

NCT02194738 2026-05-29

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

8,300 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 3 Active not recruiting

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03793179 2026-05-29

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

600 enrolled

Lung Neoplasms

NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

117 enrolled

Phase 1/2 Active not recruiting

Lung Neoplasms

NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04216316 2026-05-28

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

12 enrolled 25 charts

Lung Neoplasms

NCT04514484 2026-05-28

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

8 enrolled 32 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

41 enrolled

Lung Neoplasms

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

138 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 3 Active not recruiting

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT04214262 2026-05-13

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

480 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04310020 2026-05-13

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

47 enrolled